25 26 Short title: Tyrosine phosphorylation of ACLY controls tumor metabolism 27 34 Phone: 215-614-0978 35 FAX: 215 662-7529 36 37 2 A fundamental requirement for growth of rapidly proliferating cells is metabolic adaptation to 38 promote synthesis of biomass 1 . ATP citrate lyase (ACLY) is a critical enzyme responsible for 39 synthesis of cytosolic acetyl-CoA, the key building component for de novo fatty acid synthesis and 40 links vital pathways such as carbohydrate and lipid metabolism 2 . The mechanisms of ACLY 41 regulation are not completely understood and the regulation of ACLY function by tyrosine 42 phosphorylation is unknown. Here we show using mass-spectrometry-driven phosphoproteomics and 43 metabolomics that ACLY is phosphorylated and functionally regulated at an evolutionary conserved 44 residue, Y682. Physiologic signals promoting rapid cell growth such as epidermal growth factor 45 stimulation in epithelial cells and T-cell receptor activation in primary human T-cells result in rapid 46 phosphorylation of ACLY at Y682. In vitro kinase assays demonstrate that Y682 is directly 47 phosphorylated by multiple tyrosine kinases, including ALK, ROS1, SRC, JAK2 and LTK. 48 Oncogenically activating structural alterations such as gene-fusions, amplification or point mutations 49 of ALK tyrosine kinase result in constitutive phosphorylation of ACLY in diverse forms of primary 50 human cancer such as lung cancer, anaplastic large cell lymphoma (ALCL) and neuroblastoma. 51 Expression of a phosphorylation-defective ACLY-Y682F mutant in NPM-ALK+ ALCL decreases 52 ACLY activity and attenuates lipid synthesis. Metabolomic analyses reveal that ACLY-Y682F 53 expression results in increased β-oxidation of 13 C-oleic acid-labeled fatty acid with increased labeling 54 of +2-citrate (p<0.01) and +18-oleyol carnitine (p<0.001). Similarly, oxygen consumption rate (OCR) 55 is significantly increased in cells expressing ACLY-Y682F (p<0.001). Moreover, expression of ACLY-56 Y682F dramatically decreases cell proliferation, impairs clonogenicity and abrogates tumor growth 57
3 ACLY, a key metabolic enzyme involved in glucose and lipid metabolism, connects glycolysis to lipid 69 synthesis and plays an important role in metabolism. The conversion of glucose to fatty acids is dependent 70 on the activity of ACLY which converts mitochondria-derived citrate to cytosolic acetyl-CoA 3 . Acetyl-71
CoA is an important precursor not only for lipid synthesis but also for cell growth and proliferation by 72 promoting the acetylation of histones for gene transcription 4 . Cell proliferation requires a constant supply 73 of lipids and lipid precursors to fuel membrane biogenesis and protein modification 5 . Glutamine can also 74 be converted to citrate by the reversal of the Krebs cycle catalyzed by isocitrate dehydrogenase and 75 aconitase 6 . ACLY supports de novo lipid synthesis and knockdown of ACLY reduces the ability of cells 76 to metabolize glucose to lipids 6 . The role of ACLY in tumor growth has been substantiated by observation 77 that the small molecule inhibitor of ACLY, SB204990, or shRNA mediated knockdown of ACLY abrogate 78 the tumor growth in xenograft models 2 . 79
80
In living cells, the activity of ACLY is dependent on its homotetramerization. The complete crystal structure 81 of ACLY has been recently solved by two independent groups 7,8 . We and others have also recently reported 82 cryo-electron microscopy structures of human ACLY, with and without bound acetyl-CoA (Wei X Nat 83 Struct Mol Biol 2019). ACLY activity is also regulated by post-translational modifications including 84 ubiquitination, acetylation 9 and serine phosphorylation 10 .
While a functional role for serine 85 phosphorylation via AKT has been demonstrated to enhance ACLY activity and regulate histone acetylation 86 in human gliomas and prostate tumors 11 , no regulatory role for tyrosine phosphorylation has been 87 established for ACLY function. Receptor tyrosine kinases are key regulators of critical cellular processes 88 such as proliferation, differentiation, cell survival, migration, cell-cycle control and metabolism 12 . 89
Mutational activation of tyrosine kinases resulting in aberrant activation of phosphorylation-mediated 90 intracellular signaling are causally linked to several diseases including cancer, diabetes, inflammation and 91 angiogenesis. Tyrosine kinase (including ALK)-mediated post-translational modification of metabolic 92 enzymes such as pyruvate kinase M2 (PKM2) regulates tumor metabolism 12 . However, a functional role of 93 tyrosine-kinase mediated phosphorylation of ACLY has not been described and the effects on tumor 94 metabolism and growth are unknown. 95
96
In our present study, we employed a mass spectrometry-based global phosphoproteomic and metabolomics 97 strategy to elucidate novel mechanisms of oncogenic tyrosine kinase-mediated regulation of metabolic 98 pathways. Our results implicate a direct link between tyrosine kinase-mediated signaling and lipid 99 metabolism that is frequently subverted by oncogenic driver tyrosine kinases in diverse forms of human 100 cancer. 101
102
To discover novel mechanisms of phosphotyrosine-mediated oncogenesis, we performed 103 phosphoproteomic analysis of eighteen lymphoma-derived cell lines including SU-DHL-1, SUP-M2 and 104
Karpas 299 harboring the t(2;5)(p23;q35) aberration which encodes the oncogenic chimeric fusion tyrosine 105 kinase NPM-ALK, and generated a compendium of phosphorylated proteins with site mapping of 881 106 phoshorylated tyrosine peptides. To identify tyrosine phosphorylation events that could be driven by 107 constitutive ALK activation, we performed clustering of pairwise correlations of 359 phosphotyrosine 108 residues in the phosphoproteomic dataset that were measured in at least 3 out of the 18 cell lines. We 109 constructed a heatmap based on Pearson correlation between phosphorylated tyrosine residues that were 110 correlated with phosphorylation of ALK Y1604 (activated ALK) (Extended Data Fig. 1a ). We observed 111 that several tyrosine residues, ALK Y1584, ALK Y1507, ALK Y1131, ALK Y1096, PKM Y105, SHC1 112 Y427 and WDR1 Y238 whose phosphorylation have been reported in ALK positive ALCL 12 were highly 113 correlated with ALK Y1604 phosphorylation (Extended Data Fig. 1a ). Notably ACLY Y131 (Pearson 114 correlation: 0.79, p-value = 0.0001035) and Y682 phosphorylation (Pearson correlation: 0.79, p<1E-4) was 115 significantly correlated with ALK Y1604 (activated ALK) (Extended Data Fig. 1a ). To determine whether 116 ACLY Y682 is regulated by ALK activity, we subjected the NPM-ALK positive SU-DHL-1 cells to a 117 selective small molecule inhibitor of ALK (CEP-26939) followed by global phosphoproteomic analysis 13, 14 . 118
We observed reduction of phosphorylation of several ALK tyrosine residues including pY1604, pY1078, 119 phosphorylation and its impact on tumor metabolism. 139
140
To further explore the effect of crizotinib on ACLY Y682 phosphorylation, 2 ALK+ ALCL cell lines (SU-141 DHL-1, DEL) and a neuroblastoma cell line (NB1) were treated with crizotinib and lysates were subjected 142 to immunoblot. Western blotting of the lysates with an anti-pACLY Y682 antibody generated to interrogate 143 its phosphorylation status revealed decreased phosphorylation of ACLY at Y682 with crizotinib treatment 144 in comparison to DMSO control ( Fig. f,g) . Furthermore, the anti-pACLY Y682 antibody was used to 6 assess the level of phosphorylated ACLY in neoplastic and physiologic conditions. Total protein lysates 146 derived from ALK+ ALCL and ALK-T-cell lymphoma cell lines were immunoblotted with anti-pACLY 147 Y682 which revealed constitutive phosphorylation of ACLY at Y682 in ALK+ ALCLs, but not in ALK-148 T-cell lymphomas (Fig. 1a ). Immunohistochemistry (IHC) performed on human tissue biopsies derived 149 from ALK+ ALCL (n=20) and ALK-ALCL (n=28) patients using pACLY Y682 and ALK antibodies (Fig. 150 1b) revealed that (19/20) 95% of ALK+ ALCLs expressed pACLY-Y682, while (6/28) 21.42% of ALK-151 ALCL expressed pACLY Y682 demonstrating significant correlation between phosphorylation of ACLY 152 at Y682 and ALK expression (X 2 =31.35; p-value < 0.01). 153 154 Next, we generated an ALK+ ALCL cell line (DEL) with lentivirus-mediated stable expression of empty 155 vector, HA-tagged ACLY-WT or ACLY-Y682F. Immunoblotting with pACLY-Y682 antibody revealed 156 that phosphorylation of ACLY Y682 was increased in DEL cells stably expressing ACLY-WT, while cells 157 expressing ACLY-Y682F exhibited basal ACLY Y682 phosphorylation which was comparable to vector 158 ( Fig. 1c ). Additionally, we stably transduced active NPM-ALK and kinase defective NPM-ALK-K210R 159 constructs in human primary T cells and lysates were prepared 8 days after transduction. Immunoblotting 160 with pACLY-Y682 antibody revealed phosphorylation of ACLY Y682 only in active NPM-ALK 161 transduced human primary T cells ( Fig. 1e ). 162
163
To evaluate the impact of ACLY Y682 phosphorylation on its enzymatic activity, we employed a malate 164 dehydrogenase-coupled assay 18 in which protein lysates were used as a source of ACLY. Assessment of 165 enzymatic activity revealed significantly decreased ACLY activity in cells expressing ACLY-Y682F in 166 comparison to ACLY-WT ( Fig.3c ). Pharmacologic inhibition of ALK using crizotinib at 300 nM for 6 167 hours in 2 ALK+ ALCL cell lines, SU-DHL-1 and DEL resulted in reduction of ACLY activity by >20% 168 and >25%, respectively (p <0.05) ( Fig. 3a,b ). Taken together, these results indicate that Y682 169 phosphorylation is critical for ALK-mediated ACLY activity. 170 7 To further explore the effect of active NPM-ALK on endogenous ACLY Y682 phosphorylation and its 172 enzymatic activity, we transfected HEK293T cells with empty vector, active NPM-ALK and kinase-173 defective NPM-ALK-K210R constructs. Western blotting revealed that active NPM-ALK phosphorylated 174 ACLY at Y682 but the kinase-defective NPM-ALK-K210R did not ( Fig. 1d ). Further, the enzymatic 175 activity of ACLY was dependent on the kinase activity of NPM-ALK. Indeed, cells expressing kinase-176 defective NPM-ALK-K210R exhibited basal levels of ACLY activity comparable to that seen in empty 177 vector-transfected cells (Fig. 3d ). Correspondingly, we further explored the effect of active NPM-ALK on 178 endogenous ACLY Y682 phosphorylation in human CD4+ cells with empty vector, active NPM-ALK and 179 kinase-defective NPM-ALK-K210R constructs and observed similar results ( Fig.1e ). 180
181
To evaluate whether NPM-ALK directly phosphorylates ACLY, we expressed recombinant GST-tagged 182 ACLY-WT and ACLY-Y682F peptides which were co-incubated with active NPM-ALK or kinase-183 defective NPM-ALK-K210R immunopurified from HEK293T cells that were transfected with respective 184 constructs in in vitro kinase assay conditions. Immunoblotting using anti-pACLY Y682-specific antibody 185 revealed that ACLY is phosphorylated at Y682 by NPM-ALK but not by the kinase-defective NPM-ALK 186 -K210R) ( Fig. 2a ). 187
188
To evaluate whether NPM-ALK interacts with ACLY, we transiently transfected vectors encoding HA-189 tagged ACLY-WT and ACLY-Y682F alone or with active NPM-ALK in HEK293T cells. Immunoblotting 190 of ALK-immunoprecipitation (IP) with anti-HA demonstrated that ACLY-WT and ACLY-Y682F interact 191 with NPM-ALK ( Fig. 1g ). Further, reciprocal IP with HA revealed NPM-ALK interaction with ACLY-WT 192 and ACLY-Y682F ( Fig. 1h ). To further evaluate whether endogenous NPM-ALK interacts with 193 endogenous ACLY, we subjected SU-DHL-1 cell lysates for ALK-immunoprecipitation (IP) with ALK 194 antibody and IgG controls and probed with anti-ACLY antibody. These data indicate that ACLY interacts 195 with NPM-ALK in endogenous conditions (Fig.1j) . phosphorylates ACLY Y682 in H3122 cell line (Extended Data Fig. 3a ). We then performed in vitro kinase 204 assays to evaluate whether EML4-ALK directly phosphorylates ACLY. To this end, we incubated 205 recombinant GST-tagged ACLY-WT and ACLY-Y682F peptides with immunopurified EML4-ALK from 206
HEK293T cells transfected with EML4-ALK followed by immunoblotting with anti-pACLY Y682. The 207 results revealed that EML4-ALK directly phosphorylates ACLY Y682 ( Fig. 2b ). Immunohistochemistry 208 (IHC) using tissue microarrays (TMA) revealed positive reactivity for pACLY Y682 in EML4-ALK+ 209 primary lung cancer (n=5) (Extended Data Fig. 3b ). Furthermore, we detected constitutive phosphorylation 210 of ACLY Y682 in the neuroblastoma cell line (NB1) 21 ( Fig. 1g ) which is characterized by ALK 211
amplifications. 212 213
To investigate whether point mutations in full-length ALK also promote ACLY Y682 phosphorylation, we 214 used recombinant ALK R1275Q which is observed in sporadic and familial neuroblastoma 22 and ALK 215 C1156Y a known crizotinib resistance mutation in EML4-ALK positive lung cancer 23 . In vitro kinase 216 assays revealed increased Y682 phosphorylation in GST-ACLY in the presence ALK R1275Q and ALK 217 C1156Y when compared to wild type full-length ALK (Fig. 2c ). In this regard, we quantified the 218 densitometry values and observed a seven-old increase in ACLY Y682 phosphorylation in the presence of 219 ALK mutations (Fig. 2d ). These findings indicate that activating point mutations in full length ALK 220 (R1275Q) increase Y682 phosphorylation of ACLY and that the crizotinib resistance mutation (C1156Y) 221 led to enhanced ALK-mediated phosphorylation of ACLY Y682. The results indicate that diverse genomic 222 mechanisms of oncogenic ALK activation lead to constitutive phosphorylation of ACLY Y682. 223 9 224
Having observed robust phosphorylation of ACLY Y682 in cells harboring ALK gene fusions, 225 amplifications and activating mutations, we sought to investigate whether ACLY could serve as a substrate 226 for other tyrosine kinases. In vitro kinase assays using recombinant proteins showed that multiple tyrosine 227 kinases namely SRC ( Fig. 2e ), JAK2 (Fig. 2f ), ROS1 ( Fig. 2g ) and LTK (Fig. 2h ) directly phosphorylate 228 ACLY Y682. Furthermore, IHC demonstrated ACLY Y682 phosphorylation in tissue biopsies of EGFR 229 mutant lung cancer (n=5) (Extended Data Fig. 3d ) and HER2-amplified breast cancer (n=5) (Extended Data 230 tyrosine kinases, we reasoned that physiologic cellular growth signals such as growth factor stimulation 234
and T-cell receptor signaling may regulate the tyrosine phosphorylation of ACLY Y682. To test this 235 hypothesis, we stimulated two epithelial cell lines (HeLa and A549) with epidermal growth factor (EGF) 236 and performed western blotting with anti-pACLY Y682. Rapid phosphorylation of ACLY Y682 was 237 observed upon EGF stimulation in a time-dependent fashion in both epithelial cell contexts ( Fig. 1,k ,l). To 238 further substantiate a role for Y682 phosphorylation in the regulation of physiologic processes, we 239 evaluated pACLY Y682 in primary peripheral blood T cells following stimulation with anti-CD3/CD4 24,25 . 240 These experiments revealed rapid and time-dependent phosphorylation of ACLY Y682 (Fig. 1m ). Taken 241 together, these results indicate that diverse physiologic stimuli engaging multiple tyrosine kinase-mediated 242 pathways regulate the phosphorylation of ACLY Y682. 243
244
Having established that phosphorylation of ACLY Y682 regulates its enzymatic activity, we sought to 245 evaluate its impact on citrate metabolism. We performed 13 C-glucose labeling analysis using high-246
performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) in DEL cells pretreated with 247
DMSO and crizotinib (Schematic shows 13 C-glucose derived metabolites where carbons are depicted as 248 (red circles) Fig. 3e ). As shown in Fig. 2f , ALK inhibition led to time-dependent accumulation of 13 C2-249 citrate (m+2 red) in comparison to DMSO control. This was associated with concomitant time-dependent 250 reduction of 13 C2-acetyl-Co-A (m+2 red) in response to ALK inhibition by crizotinib ( Fig. 2g ). Similar 251 results were observed in another ALCL-derived cell line, SUD-HL1 (Extended Data Fig. 4b ). This was 252 associated with concomitant time-dependent reduction of 13 C2-acetyl-Co-A (m+2 red) and 13 C2-malonyl-253 co-A (m+2 red) in response to ALK inhibition (Extended data Fig.5c,d) . Similarly, stable expression of the 254 ACLY Y682F mutant in the ALK+ALCL cell line (DEL) led to accumulation of 13 C2-citrate (m+2) and 255 reduced 13 C2-acetyl-Co-A (m+2) compared to ACLY-WT ( Fig. 3h,i) . 256
257
We next explored the functional role of ALK-mediated ACLY Y682 phosphorylation in de novo 258 lipogenesis using metabolomic profiling. DEL cells were cultured in the presence of 13 C-glucose or 13 C-259 glutamine for 24 hours and lipids were extracted and converted into fatty acid methyl esters analyzed by 260 GC-MS (Fig. 3j) . These analyses demonstrated that ALK enhances the rate of incorporation of 13 C-glucose 261 and 13 C-glutamine derived 13 C-into palmitate in DEL cells (Fig. 3k,l) . This was more pronounced for 262 glutamine-derived 13 C incorporation (+16) into cellular palmitate relative to glucose-derived 13 C 263 incorporation (+10 (Fig. 3l) . These data indicate that NPM-ALK regulates de novo lipid synthesis. The 264 effect of ACLY on de novo lipogenesis was then evaluated using DEL cells stably expressing ACLY-WT 265 and ACLY-Y682F cells using similar experimental conditions. As shown in Fig. 3m and Fig. 3n , these 266 experiments revealed that ACLY-Y682F led to significant decrease in 13 C incorporation into cellular 267 palmitate (p < 0.001) in either 13 C-glucose-or 13 C-glutamine-cultured conditions. Taken together, these 268 results indicate that ACLY Y682 phosphorylation promotes de novo lipogenesis. 269
270
To determine whether phosphorylation of ACLY Y682 impacts fatty acid oxidation, DEL cells stably 271 transduced to express ACLY-WT or ACLY-Y682F mutant were cultured in 13 C-oleic acid-containing 272 media for LC-MS/MS analysis to quantitate the intermediates derived from β-oxidation of fatty acid 273 (Extended Data Fig. 4e ). Complete oxidation of 13 C-oleic acid in mitochondria yields eight acetyl units 274 which are incorporated in the form of citrate ( 13 C2-citrate) labeled on two carbons 26 . LC-MS/MS analyses 275 demonstrated increased 13 C2-citrate and oleoyl carnitine (m+18) metabolite levels in cells expressing 276 ACLY-Y682F when compared to ACLY-WT (Extended Data Fig. 4f,g) . Taken together, these studies 277 indicate that ACLY Y682 phosphorylation decreases fatty acid oxidation. 278
279
The ability to adapt oxygen consumption requirements to favor generation of biomass irrespective of 280 ambient oxygen conditions is a critical necessity during rapid physiologic and oncogenic cell growth [27] [28] [29] . 281
To evaluate the role of ACLY Y682 phosphorylation on oxygen consumption rates (OCR), we measured 282 the basal OCR in DEL cell lines stably expressing ACLY-WT and ACLY-Y682F 30 in the presence of 283 palmitate or oleic acid. These studies showed increased basal OCR in ACLY Y682F cells when compared 284 to ACLY-WT cells (Extended Data Fig. 4h ). Taken together these data indicate that phosphorylation of 285 ACLY Y682 favors generation of lipid biomass and anabolic metabolism. 286
287
We investigated the effect of small molecule inhibitors of ACLY (BMS 303141) 31 and ALK (crizotinib) 145 288 on cell proliferation of ALK+ALCL cell lines DEL, SUPM2 and SUP-CR500 for 24, 48 and 72 hours. Cells 289 treated with the ACLY inhibitor alone or in combination with crizotinib showed significant reduction of 290 cell proliferation when compared to DMSO control, similar to ALK inhibition (Fig. 4a,b,c) . Similarly, we 291 investigated the functional role of phosphorylation of ACLY Y682 in DEL cells stably expressing vector, 292 ACLY-WT or ACLY-Y682F and assessed cell proliferation over 24, 48 and 72 hours. Cells expressing 293 ACLY-Y682F showed significant reduction of proliferation (>69%, p <0.005) when compared to those 294 expressing ACLY-WT (Fig. 4d) . 295
296
We employed methylcellulose-based colony formation assays to assess the clonogenic potential of ALK 297 positive DEL cells expressing ACLY-WT and ACLY-Y682F mutant using vector only-expressing cells as 298 control. These assays revealed significantly higher (>70%, p<0.005) colony formation in ACLY-WT when 299 compared to ACLY-Y682F mutant cells (Fig. 4e,f) . To evaluate in vivo tumorigenicity, we established 300 xenografts of DEL cells stably expressing vector control (n=5), ACLY-WT (n=5) and ACLY-Y682F (n=5) 301 by subcutaneous injection of 1X10 7 cells into SCID-BEIGE mice and examined tumor growth over time. 302
After 21 days, all mice xenografted with vector only and ACLY-WT developed large tumors (>550 mm 3 303 volume). By contrast, only one out of five mice injected with ACLY-Y682F cells developed a small tumor 304 in vivo while the remaining four mice were tumor-free. The tumor sizes ( Fig. 4g ) and volumes (Fig. 4h ) 305
show significantly diminished tumor growth in ACLY-Y682F expressing DEL cells. Accordingly, whereas 306 all mice harboring ACLY-Y682F expressing DEL xenografts were alive beyond 34 days, all animals 307 xenografted with ACLY-WT and vector-only expressing DEL cells did not survive beyond 23 days (Fig.  308   4i) . Taken together, these results indicate that phosphorylation of ACLY Y682 is critical for tumor growth. 309 We show here that phosphotyrosine-mediated regulation of ACLY activity plays a critical functional role 313 in the generation of acetyl-CoA and subsequent lipid metabolism that contribute to tumor growth. Given 314 that cell proliferation requires de novo fatty acid synthesis, tyrosine kinase-mediated regulation of ACLY 315 activity provides a direct mechanism for connecting growth factors and other cellular signals such as 316 lymphocyte antigen receptors signaling to lipid metabolism in order to support membrane synthesis 317 required for cell growth. In this regard, our studies demonstrate that Y682 phosphorylation of ACLY is 318 regulated by physiologic signals such as EGF and CD3-mediated T-cell activation. These findings suggest 319 that reversible physiological tyrosine phosphorylation at ACLY Y682 may serve as a switch that directly 320 controls the ability of critical cellular events to immediately trigger lipid synthesis required for cell 321 proliferation. Oncogenically-activated tyrosine kinases are among the most common primary drivers of 322 diverse cancers and may subvert this mechanism by constitutive phosphorylation of Y682 ACLY and 323 stimulation of ACLY activity to promote lipid synthesis and tumor proliferation and may contribute to 324 acquired resistance to small molecular inhibitors. These observations indicate that direct inhibition of 325 ACLY Y682 phosphorylation may offer an attractive therapeutic opportunity for diverse cancers. (1mM), in a humidified atmosphere containing 5% CO 2, respectively. 338
HA-tagged ACLY-WT and ACLY-Y682F overexpression in HEK293T cells: ACLY was transiently 339
transfected in HEK293T cells using Polyjet (SignaGen Lab) with pLenti vector and pLenti-GIII-CMV-340
Human-ACLY HA-tagged constructs (Abmgood, Burlington, Canada) by following the manufacturer's 341 guidelines. Empty vector lacking the ACLY sequence was used as control. ALCY-Y682F mutation was 342 generated by Dpn I-mediated site-directed mutagenesis using Phusion High-Fidelity DNA Polymerase 343 using ACLY-HA as a template. 344
ACLY-WT and ACLY-Y682F mutant lentivirus transduction in DEL cells: To stably overexpress 345
ACLY-WT and ACLY-Y682F mutant form of human full length constructs in DEL, lentivirus transduction 346 particles were generated using HEK293T packaging cells transfected by vector plasmid constructs such 347 as psPAX2 and pMD2.G containing full length human ACLY-WT and ACLY-Y682F mutant with HA 348 and GFP tags. The virus particles were transduced into DEL cell line and expanded for three passages; antibody and resolved on SDS-PAGE (NuPAGE 4-20%), the gel was stained with G250 and the bands were 365 excised. Phosphotyrosine containing peptides were purified and subjected to tandem mass spectrometry for 366 protein identification. 367
Co-immunoprecipitation and immunoblotting: HEK293T cells were grown in 10-cm plates. After 24 368 hours, cells were transiently transfected with HA-tagged ACLY-WT, ACLY-Y682F, active NPM-ALK 369 kinase-defective NPM-ALK-K210R, construct expressing EML4-ALK [E6A20] and the empty vector 370 (pCDH-puro) using Polyjet transfection reagent (Signagen) as per the manufacturer's instructions. 371
Plasmids used to express active NPM-ALK and kinase defective NPM-ALK-K210R has been described 372 previously 24 . The constructs expressing EML4-ALK [E6A20] and the empty vector (pCDH-puro) were 373 generously provided by Dr. Robert C. Doebele, University of Colorado, Denver, CO. Forty-four hours 374 post-transfection, cells were lysed in 1000 μl of RIPA lysis buffer/plate by sonication. Lysates were 375 centrifuged (15,000 × g, 10 min, 4°C) and thesupernatant was incubated overnight at 4°C with anti-HA or 376 anti-ALK antibodies. Fifty μl of protein A/G PLUS-agarose (Santa Cruz Biotechnology) were added for 6 377 h. After four washes with RIPA lysis buffer, the precipitated proteins were heated in 2 X SDS-PAGE sample 378 buffers at 95°C for 6 min and analyzed by western blotting. Membranes were blocked in TBST plus 5% 379 defatted milk followed by overnight incubation at 4°C with primary antibodies as indicated, i.e. anti-HA, 380
anti-pACLY Y682, anti-ALK and anti-pALK Y1604. Incubation with the appropriate secondary HRP-381 labeled antibody was followed by detection with ECL western blotting substrate (Roche Applied Science). 382
In vitro kinase assay using NPM-ALK: Immunoprecipitation of ALK was carried out as described above. 383
Sepharose-bound immune complexes in lysis buffer were washed and resuspended in kinase buffer (50 mM 384
Tris.HCl, pH 7.5, 10 mM MgCl2, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 1mM DTT and 200 385 µM ATP). GST-ACLY-WT and GST-ACLY-Y682F recombinant peptides were expressed in E.coli, BL21 386 strain and purified by using GST-agarose beads and eluted. Purified GST-ACLY and GST-Y682F peptides 387
were incubated with ALK immunocomplex from NPM-ALK and NPM-ALK (K210R) co-transfected cell 388 lystaes in the presence of kinase buffer and 0.5 mM ATP for 30 min at 30°C. Samples were heated at 95°C 389 for 5 min and separated on a 4-20% gel by SDS-PAGE and followed by western blotting and probed with 390 anti-GST, ant-pACLY Y682, anti-ALK and ant-pALK Y1604 antibodies. 391
In vitro kinase assays using multiple oncogenic tyrosine kinases: Recombinant GST-ACLY-WT and 392
GST-ACLY-Y682F peptides were subjected to in vitro kinase assay using various oncogenic tyrosine 393 kinases as described above. In brief, GST-ACLY-WT and GST-ACLY-Y682F beads were incubated with 394 100 ng of recombinant ALK, ALK C1156Y (mutated in EML4-ALK), ALK R1275Q (mutated in 395 neuroblastoma), SRC kinase, JAK2, ROS1 and LTK for 30 min at 30°C in kinase buffer. Samples were 396 heated at 95°C for 5 min, separated on a 4-20% gel by SDS-PAGE and followed by western blotting using 397 anti-GST, ant-pACLY Y682, anti-ALK and ant-pALK Y1604, anti-pSRC Y416, anti-pJAK2 Y1007, anti-398 pROS1 Y2274 and anti-LTK antibodies. 399 ACLY enzymatic activity assay: ACLY enzyme activity was determined using the malate dehydrogenase 400 (MDH)-coupled method as described earlier with little modification 9 . Briefly, cell lysates were incubated 401 in reaction buffer containing 10 mM potassium citrate, 10 mM MgCl2, 1 mM DTT, 10 U malic 402 dehydrogenase, 0.3 mM CoASH, 0.1 mM NADH in 50 mM Tris (pH 7.5) and the reaction was initiated by 403 adding 0.2mM ATP in a final volume of 100 ul, incubated at 37°C, and NADH oxidation was continuously 404 monitored every 5 min for 60 min using a microplate reader. To measure the effect of a small molecule 405 inhibitor of ALK, DEL and SU-DHL1 cells were pretreated with crizotinib at 300 nM for 6 hours. For the 406 control experiments, lysis buffer was used in place of cell lysates for nonspecific NADH oxidation. The 407 relative ACLY activities were calculated by normalization to the total protein abundance of the extracts in 408 triplicate. 409 Immunohistochemistry (IHC) for pY682-ACLY expression: Formalin fixed, paraffin sections were cut 410 at 5 microns and rehydrated to water. Heat induced epitope retrieval was performed with FLEX TRS Low 411 pH Retrieval buffer (6.10) for 20 minutes. After peroxidase blocking, the rabbit anti p-ACLY Y682 412 antibody was applied at a dilution of 1:250 at room temperature for 60 minutes. The FLEX HRP EnVision 413
System was used for detection. DAB chromagen was then applied for 10 minutes. Slides were 414 counterstained with hematoxylin. 415 13 C-glucose isotopomer-labeled metabolomics analysis: DEL cells were treated with DMSO or crizotinib 416 (300 nM) for 3 hours in complete RPMI media containing 10% FBS before 13 C-glucose flux analysis. Cells 417 were washed in PBS and resuspended at 5 × 10 6 cells in glucose-free RPMI media containing 10% FBS in 418 the presence or absence of crizotinib for each condition (N=3). The cells were supplemented with U-13 C-419 glucose at final concentration of 15 mM and incubated for 30 min and 60 min at 37°C incubator. Cell pellets 420 were snap frozen in liquid nitrogen and processed for LC-MS/MS analysis as detailed in the supplementary 421 materials. 422 13 C-glucose and 13 C-glutamine labeling lipid synthesis metabolomics analysis: DEL cells were grown 423 in the presence of DMSO or crizotinib (50 nM) for 24 hours in complete RPMI media containing 10% FBS 424 and 13 C-glucose (25mM) in three biological replicates. After 24 hours, equal amount of cells (5 X 10 6 cells) 425 from DMSO and crizotinib-treated flasks were spun down and cell pellets were snap frozen in liquid 426 nitrogen. Similarly, DEL cells were grown in the presence of DMSO or crizotinib (50 nM) for 24 hours in 427 glutamine-free RPMI media containing 10% FBS and 13 C-glutamine (3mM) in three biological replicates. 428
After 24 hours, equal number of cells (5 X 10 6 cells) from DMSO and crizotinib-treated flasks were spun 429 down and cell pellets were snap frozen in liquid nitrogen and processed for gas chromatography/mass 430 spectrometry (GC/MS) for analysis of lipid synthesis. 431 Fatty acid oxidation: DEL cells stably expressing ACLY-WT and ACLY-Y682F (5 X 10 6 cells/condition) 432
were seeded in serum/glucose free RPMI medium for 3 hours before the experiment. After 3 hours of 433 starvation, cells were incubated in the presence of 400 μM 13 C-palmitic acid (Sigma) or 400 μM 13 C-oleic 434 acids (Sigma) with 2.5 mM glucose in RPMI medium for 2 hours. Cells were immediately snap-frozen 435 using liquid nitrogen and kept at −80°C until extraction of metabolites, as described previously 25 . 436
Oxygen consumption rate: Oxygen consumption rate (OCR) was measured using a Seahorse XF24 437 extracellular flux analyzer (Seahorse Bioscience) as described by the manufacturer protocol. Twenty four 438 hours before the experiment, DEL cells stably expressing ACLY-WT and ACLY-Y682F were cultured in 439 complete RPMI medium. On the day of metabolic flux analysis, the culture medium was replaced with 675 440 µl of unbuffered serum/glucose free RPMI and seeded on Seahorse XF-24 plates at a density of 1 × 10 5 441 cells per well and incubated at 37 °C in a non-CO2 incubator for 1 hour. All injection reagents were adjusted 442 to pH 7.4. Baseline rates were measured at 37°C before injecting final volume of 1.0 mM glucose and 400 443 uM palmitate or oleate. After the addition of 1.0 mM glucose and each fatty acid, OCR readings were 444 automatically calculated from five replicates by the Seahorse XF-24 software. 445 EGF stimulation of HeLa and A549 cells: HeLa and A549 cells were grown in 10-cm plates in complete 446 DMEM and RPMI media, respectively for 48 hours. At 80% confluency, cells were serum starved for 16 447 hours. Cells were stimulated with 2.5 ng/ml EGF for 5, 10 and 20 minutes. Cells were then processed for 448 western blotting as described above with antibodies for anti-EGFR, anti-phospho EGFR, anti-ACLY, anti-449 ERK1/2 and anti-pERK1/2 and anti-pACLY Y682. 450
Anti-CD3/CD4 stimulation of human primary T cells: Human primary T cells were purified from whole 451
blood of healthy donors provided by the Human Immunology Core facility at the University of 452
Pennsylvania. For each condition, 6 x10 6 cells were stimulated with 10ug/ml of anti-CD3/CD4 antibody in 453 PBS at room temperature for 5, 10 and 20 minutes. Cell lysates were processed for western blotting as 454 20 (ThermoFisher) in-line with a Paradigm MS2 HPLC (Michrom Bioresources) was employed for acquiring 505 high-resolution MS and MS/MS data. Ten microliters of the phospho-enriched peptides were loaded onto 506 a sample trap (Captrap, Bruker-Michrom) in-line with a nano-capillary column (Picofrit, 75 μm i.d.x 15 μm 507 tip, New Objective) packed in-house with 10 cm of MAGIC AQ C18 reverse phase material (Michrom 508 Bioresource). Two different gradient programs, one each for MOAC and phosphotyrosine 509 immunoprecipitation samples, were used for peptide elution. For MOAC samples, a gradient of 5-40% 510 buffer B (95% acetonitrile/1% acetic acid) in 135 min and 5 min wash with 100% buffer B followed by 30 511 min of re-equilibration with buffer A (2% acetonitrile/1% acetic acid) was used. For phosphotyrosine 512 immunoprecipitation samples, which were a much less complex mixture of peptides, 5-40% gradient with 513 buffer B was achieved in 75 min followed by 5 min wash with buffer B and 30 min re-equilibration. Flow 514 rate was ~0.3 μl/min. Peptides were directly introduced into the mass spectrometer using a nano-spray 515 source. Orbitrap was set to collect 1 MS scan between 400-2000 m/z (resolution of 30,000 @ 400 m/z) in 516 orbitrap followed by data dependent CID spectra on top 9 ions in LTQ (normalized collision energy ~35%). 517
Dynamic exclusion was set to 2 MS/MS acquisitions followed by exclusion of the same precursor ion for 518 2 min. Maximum ion injection times were set to 300 ms for MS and 100 ms for MS/MS. Automatic Gain 519 Control (AGC) was set to 1xe 6 for MS and 5000 for MS/MS. Charge state screening was enabled to discard 520 +1 and unassigned charge states. Technical duplicate data for each of the MOAC elutions (ammonium 521 hydroxide and pyrrolidine) and triplicate data for the phosphotyrosine immunoprecipitation samples were 522
acquired. 523
Bioinformatics analysis: RAW mass spectrometric data were analyzed in MaxQuant environment (version 524 1.5.3.30) and employed Andromeda for database search 27 The MS/MS spectra were matched against the 525 human Uniprot FASTA database downloaded on 04/27/2016. Enzyme specificity was set to trypsin and a 526 maximum of 2 missed cleavages. Carbamidomethylation of cysteine was set as a fixed modification while 527 methionine oxidation, protein N-acetylation and serine/threonine/tyrosine phosphorylation were set as 528 variable modifications. The required false discovery rate (FDR) was set to 1% both for peptide and protein 529 21 levels. In addition, "match between runs" option with a window of 1.5 minute was allowed. Log2-530 transformed centered intensities of phosphopeptides were used for further analysis. 531
Statistical analysis: Statistical analysis and graphical presentation was performed using GraphPad Prism 532 4.0. 533 534
